WAGNER CHARLES F JR

CFO Charles F Wagner Jr sells 9,532 VRTX shares at $461.00; holds 37,725 remaining post-sale

Charles F Wagner Jr, EVP and Co-President, sold 9,532 shares of Vertex Pharmaceuticals on 2026-01-06 at $461.00 for $4,394,252.00, reducing his holdings from 47,257 to 37,725 shares (-20.2%). This represents his third transaction in just over a month: his SAME-TICKER HISTORY shows two sells on 2025-12-03 followed by this sale, establishing a recent pattern of systematic disposition. The company's fundamentals remain strong (quarterly revenue $3,076,400,000.00, net income $1,082,900,000.00, +11.7% YoY revenue growth), though the enterprise trades at a P/E of 32.44 and the stock currently sits at $469.68, near recent highs. Notably, across his prior 3 measurable same-ticker sells, Wagner has achieved a 2-of-3 well-timed rate at the 90-day mark, suggesting historical accuracy in exit timing at this specific security; however, the two most recent sales (2025-12-03) lack 90-day outcome data and warrant future monitoring.

EVP/CFO Wagner sells 14,000 VRTX shares for $6,384,000; retains 37,725 shares post-sale.

Charles F. Wagner Jr., EVP and Chief Operating & Financial Officer, executed 2 separate open-market sales totaling 14,000 shares for $6,384,000.00 at blended average price $456.00 on 2025-12-03, reducing his holdings by 27.1% from 51,725 to 37,725 shares. Current stock price of $455.48 is +9.2% over the past 30 days and +15.0% over 90 days, indicating robust near-term price momentum at the time of the sale. Wagner's same-ticker history at VRTX shows 2 of 4 prior measurable sales were well-timed (negative 90-day returns), though his cross-ticker track record of 6 prior sales shows modest underperformance with an average 90-day return of -1.4% and a well-timed rate of 50.00%. The company's fundamentals reflect a profitable operating business with $3.1B in latest-quarter revenue and +11.7% annual growth, though full-year net income was negative, warranting attention to underlying operating trends.

VRTX CFO Wagner sells 3,298 shares at $500.00; holds 51,671 post-transaction

CFO Charles F. Wagner Jr. sold 3,298 shares of Vertex at $500.00 on 2025-03-10, reducing his position by 6.0% to 51,671 shares. The transaction occurred near the 52-week high (current price $495.42 is -4.1% from high of $516.74), and the stock is up 5.4% over the past 30 days and 6.7% over 90 days. Wagner's prior sales at VRTX show mixed timing: his most recent VRTX sale (2024-11-11) experienced a -9.6% 30-day decline and -9.4% 90-day decline, while earlier 2024 sales saw positive returns, with only 1 of 3 measurable VRTX sales timed well at the 90-day mark. The company fundamentals show revenue of $2,771,900,000.00 and net income of $1,045,400,000.00 for the latest quarter, with annual revenue growth of +11.7%, though it was unprofitable over the most recent full fiscal year. This sale alone does not constitute a material signal given the moderate position reduction and mixed prior execution at this ticker.

CFO Charles F Wagner Jr sold 3,000 shares of VRTX at $518.27; post-transaction holdings 44,137 shares.

CFO Charles F Wagner Jr sold 3,000 shares at $518.27 on 2024-11-11, reducing holdings by 6.4% to 44,137 shares. The transaction was executed near the 52-week high of $516.74, with the current price now at $494.61 (down 4.3% from that peak). Wagner's prior trades at VRTX show a consistent pattern: his 4 prior VRTX sales generated positive 90-day returns (ranging from +3.8% to +20.7%), meaning the stock rose after each sale. His timing pattern at this ticker has been 0 of 4 well-timed at the 90-day mark—every prior sale was followed by stock appreciation. Given that the current price sits below the transaction price, the near-term direction remains uncertain, but the historical context shows Wagner's VRTX sales have not preceded declines.